Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?Cavernous sinus syndrome caused by metastatic colon carcinomaRandomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancerProfiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapyColorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program.Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality.Disseminated intravascular coagulation and immune hemolytic anemia, possibly Evans syndrome, after oxaliplatin and bevacizumab infusion for metastatic colon adenocarcinoma: a case report and literature review.Assessing the quality of initial consultations regarding adjuvant colon cancer therapyReversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis.The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial.The Prognostic Value of Patient-Reported Outcome Data in Patients With Colorectal Hepatic Metastases Who Underwent Surgery.Recent data with oxaliplatin-containing regimens in the adjuvant treatment of colorectal cancer.Current data with HMG-CoA reductase inhibitors (statins) for colorectal cancer prevention.A case of oxaliplatin-related posterior reversible encephalopathy syndrome.Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.Systematic review of management of colorectal cancer in elderly patients.Preclinical data targeting vascular endothelial growth factor in colorectal cancer.Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer.Practical aspects of managing gastrointestinal stromal tumors.Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer.Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era.Literature review and practical aspects on the management of oxaliplatin-associated toxicity.Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report.Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study.A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).
P1433
Q26830362-6DBE6EA0-E879-4A37-BC0D-9811040494C0Q28239646-C2022663-F42B-48A2-95F8-CB90A6B10E18Q28248065-E81C854D-881C-4995-B15A-25193A785E80Q28284462-EA7BE8A7-942A-4624-BD8C-73AD67606F62Q30251582-F46AA91E-F4A7-4CDF-A543-263DDF8146B0Q30251806-F3F510D7-BD92-4A0E-AD69-FE2735365C1CQ30300932-7807CB05-5112-41D1-9390-25A53943141DQ30435841-A2BDB3BE-CAA1-4775-AB0D-252415CBE051Q30457337-6CBAD9FE-31FA-45F0-99AF-830D9319A7F9Q30885912-953204C2-8130-4DDA-B114-4AF97B14EE3FQ30981132-962E8C9F-CC00-4E41-8751-EECA279DE7FDQ30991630-47FF1603-6B7E-4FD1-88DC-51BE7E9B622BQ30999731-3932998B-5AB8-420C-9D50-BCAE231F2CDDQ31026317-A61DED9F-C5D7-4E1C-9B7F-1E0F7F1E3AF7Q31101742-6C78515B-8065-4F34-AE90-F38F2CE838EAQ31150472-10B1C703-8A9B-4555-8DA1-894C0EBC8F1BQ31150475-6278F849-2660-4304-8315-EF9D79D23504Q33196462-52DECC21-7890-4BCE-BB4F-788F5F20D84DQ33207846-50AD5F61-9DCD-41A6-9434-7DAA26A45AABQ33228875-D231B995-15A8-47A3-998A-3ECE5DFDA566Q33255975-28676E75-81F0-4909-B3F6-4B33A52D5CF8Q33259668-659012E8-844B-4B33-988C-01005C5D11CEQ33263451-2627FDC8-5A84-4318-B91B-7170A6947D3DQ33269959-AA0F5B4E-D217-40F0-B354-8A7072840860Q33368734-9BF53D26-E58A-4DFE-BE43-468FAB57376EQ33369602-F4992B44-34FA-45D5-8F13-0E9C527C1EB3Q33376153-BE28164E-26C7-4BF7-A44C-BC033E88974CQ33377061-E461DE6C-8911-4F63-93FF-EA0BD9FA233BQ33386599-BDF3C970-D5B8-4798-89EF-36A5510736CCQ33386601-FB118DD7-1CE2-4287-81FC-57E1FBD79F33Q33390886-54B5D0DE-FE49-4D8B-BE95-0D620D959737Q33393523-F4E818B5-5E9D-48BE-AD14-4B6B310DD27BQ33396805-87E82D9E-CA9A-4BEA-9844-9F4F36637410Q33398649-9505D684-EF5F-4835-9989-49087BEA3678Q33411292-71F692F7-73EF-4526-8344-EF4F4DB58A4DQ33416751-F679325A-4405-4804-91F3-E5328842FFDAQ33418980-9D79007D-6296-4524-A1DA-628E2B27422CQ33430730-675669FF-B2DE-4DB9-A7D3-7AB7CB51D396Q33433282-8C25629E-A9B0-4A52-9632-CCC4A905740DQ33434468-13166800-56EA-4257-BD17-759B1E6833E4
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Elsevier
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Clinical Colorectal Cancer
@ast
Clinical Colorectal Cancer
@de
Clinical Colorectal Cancer
@en
Clinical Colorectal Cancer
@es
Clinical Colorectal Cancer
@it
Clinical Colorectal Cancer
@nl
type
label
Clinical Colorectal Cancer
@ast
Clinical Colorectal Cancer
@de
Clinical Colorectal Cancer
@en
Clinical Colorectal Cancer
@es
Clinical Colorectal Cancer
@it
Clinical Colorectal Cancer
@nl
prefLabel
Clinical Colorectal Cancer
@ast
Clinical Colorectal Cancer
@de
Clinical Colorectal Cancer
@en
Clinical Colorectal Cancer
@es
Clinical Colorectal Cancer
@it
Clinical Colorectal Cancer
@nl
P3181
P1055
P1058
P1156
P123
P1277
P1476
Clinical Colorectal Cancer
@en
P236
P3181
P407
P571
2001-01-01T00:00:00Z